Übersichtsarbeiten

2018

Jelkmann W
Activin receptor ligand traps in chronic kidney disease
Current Opinion in Nephrology and Hypertension (in press)

2017

Aapro M, von Haehling S, Jelkmann W, Link H, Meybohm P, Seiler S, Zacharowski K
Anämie- und Blutmanagement: Neubewertung in verschiedenen Indikationen
Dtsch Ärztebl 114(48), 2017 DOI: 10.3238/PersOnko/2017.12.01.17

Depping R, Oster H
Interplay between environmentally modulated feedback loops - hypoxia and circadian rhythms - two sides of the same coin?
FEBS J, 284(22):3801-3803, 2017

Jelkmann W
Watch out for a revival of peginesatide in sports
Drug Test Anal 9(2): 157-160, 2017

Mandl M, Depping R
Hypoxic Upregulation of ARNT (HIF-1β): A Cell-Specific Attribute with Clinical Implications
Hypoxia and Human Diseases , ISBN 978-953-51-2896-0

2016

Jelkmann W, Thevis M
Could Nickel Become a Novel Erythropiesis-Stimulating Compound for Cheating Athletes?

Dtsch Z Sportmed 67:253-254, 2016

Pagel H
Hände weg von Nahrungsergänzungsmitteln!
Doping 3(2): 40-43, 2016

Jelkmann W
Features of Blood Doping

Dtsch Z Sportmed 67: 255-62, 2016

Schmidt K, Windler R, de Wit C
Communication Through Gap Junctions in the Endothelium
Adv Pharmacol 77: 209-40, 2016

von Fallois M, Depping R
Radiation response enhanced by inhibition of XPO1 in preclinical rectal cancer models
Strahlenther Onkol 2016 [Epub ahead of print]

Jelkmann W
Biosimilars - ähnlich, aber nicht gleich.
Kompendium Biosimilars. Thieme, Stuttgart, 1: 6-10, 2016

Baumann R, Depping R, Delaperrier M, Dunst J
Targeting hypoxia to overcome radiation resistance in head & neck cancers: real challenge or clinical fairytale?Expert Rev Anticancer Ther 2016 [Epub ahead of print]

Schmid H, Jelkmann W

Investigational therapies for renal disease-induced anemia

Expert Opin Inverstig Drugs 25(8): 901-16, 2016

2015

Depping R, Jelkmann W, Kosyna FK
Nuclear-cytoplasmatic shuttling of proteins in control of cellular oxygen sensing

J Mol Med (Berl) 93(6):599-608 doi: 10.1007/s00109-015-1276-0, 2015

 

Jelkmann W

The ESA scenario gets complex: from biosimilar epoetins to activin traps

Nephrol Dial Transplant 30:553-559, 2015

 

Pries AR, Badimon L, Bugiardini R, Camici PG, Dorobantu M, Duncker DJ, Escaned J, Koller A, Piek JJ, de Wit C

Coronary vascular regulation, remodelling and collateralization: mechanisms and clinical implications on behalf of the working group on coronary pathophysiology and microcirculation

Eur Heart  pii:ehv100, 2015

2014

 

Ebert B, Jelkmann W
Intolerability of cobalt salt as erythropoietic agent.
Drug Test Anal
6(3): 185-9, 2014

 

Elliott S, Sinclair A, Collins H, Rice L, Jelkmann W

Progress in detecting cell-surface protein receptors: the erythropoietin receptor example

Ann Hematol 93: 181-192, 2014

 

 

Mandl M, Depping R

Hypoxia-inducible ARNT (HIF-1β): a rare exception?

Mol Med 10.2119/molmed.2014.00032 [Epub ahead of print]

 

Jelkmann W

Xenon Misuse in Sports-Increase of Hypoxia-Inducible Factors and Erythropoietin, or Nothing but "Hot Air"?

Dtsch Z Sportmed 65:267-271, 2014

 

Windler R, de Wit, C

The Ca2+-dependent K-channel KCa3.1 as a therapeutic target in cardiovascular disease
Eur Heart J Suppl 16: A30-A32, 2014

 


 

2013

Jelkmann I, Jelkmann W
Impact of erythropoietin on intensive care unit patients
Transfus Med Hemother 40:310-318, 2013

Jelkmann W

Körpereigene Produktion von Erythropoietin
Dtsch Z Sportmed 64:327-332, 2013

 

Jelkmann W
Physiology and pharmacology of erythropoietin
Transfus Med Hemother 40:302-309, 2013

Jelkmann W, Elliott S
Erythropoietin and the vascular wall: The controversy continues

Nutr Metab Cardiovasc 23:37-43, 2013

 

Vaccarino V, Badimon L, Corti R, de Wit C, Dorobantu M, Manfrini O,
Koller A, Pries A, Cenko E, Bugiardini R
Presentation, management, and outcomes of ischaemic heart disease in women
Nat Rev Cardiol 10:508-518, 2013


2012

Aapro M, Jelkmann W, Constantinescu SN, Leyland-Jones B
Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer
Br J Cancer 106(7):1249-58, 2012

Jelkmann W

Biosimilar recombinant human erythropoietins ("epoetins") and future erythropoiesis-stimulating treatments
Expert Opin Biol Ther 12 (5):581-92, 2012


Jelkmann W
The disparate roles of cobalt in erythropoiesis, and doping relevance
Open J Hematol, 3-6, 2012

Jelkmann W
TREAT und die Frage: "Fördern ESA die Tumorprogression?"
Spektr Nephrol 25(3):21-25, 2012

Jelkmann W
The elusive erythropoietin receptor (Letter)
Nephrol Dial Transplant 27(88): 3369, 2012

Jelkmann W
Erythropoietin gene doping: Facts and fictions
Sportwiss 42: 280-285, 2012

Macdougall IC, Roger SD, de Francisco A, Goldsmith DJ, Schellekens H, Ebbers H, Jelkmann W, London G, Casadevall N, Hörl WH, Kemeny DM, Pollock C
Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights
Kidney Int 81(8):727-32, 2012


2011

de Wit C

The endothelium at the brink of calamity in storage disease: more than
just overloaded with junk? (invited editorial)

Cardiovasc Res 89, 258-259, 2011

 

Jelkmann W, Lundby C

Blood doping and its detection

Blood 118(9): 2395-404, 2011

 

Jelkmann W

Blutdoping: Grundlagen, Nachweis und der Problemfall Pechstein

Spektr Nephrol 24(2): 17-21, 2011

 

Jelkmann W

Regulation of erythropoietin production

J Physiol 598.6, 1251-1258, 2011

 

Jelkmann W

Translationale Forschung: Stellenwert von EPO in der Wundheilung
DGPW-Journal 42: 34-38, 2011


Vaccarino V, Badimon L, Corti R, de Wit C, Dorobantu M, Hall A, Koller
A, Marzilli M, Pries A, Bugiardini R
Ischemic Heart Disease in Women: Are There Sex Differences in
Pathophysiology and Risk Factors?

Cardiovasc Res 90, 9-17, 2011


2010

de Wit C, Griffith TM

Connexins and gap junctions in the EDHF phenomenon and conducted vasomotor responses

Pflügers Arch 459: 897-914, 2010

 

Jelkmann W.
Biosimilar epoetins and other follow-on biologics: Update on the European experiences
Am J Hematol. 85: 771-780, 2010

 

Jelkmann W
Claudia Pechstein, ein Fall von Blutdoping? (eingel. Kommentar)
Dtsch Z Sportmed 61: 243-4, 2010

 

Jelkmann W.
Erythropoietin: back to basics
Blood 115(21):4151-2, 2010

 

Jelkmann W
The future of biosimilars
Hosp Pharm Eur 48: 32-4, 2010


2009

Jelkmann W
Erythropoiesis Stimulating Agents and Techniques: A Challenge for Doping Analysts
Curr Med Chem 16: 1236-47, 2009

 

Jelkmann W
Efficacy of recombinant erythropoietins: is there unity of international units?
Nephrol Dial Transplant 24: 1366-8, 2009


Paus R, Bodo E, Kromminga A, Jelkmann W
Erythropoietin and the skin: A role for epidermal oxygen sensing?
BioEssays 31: 344-8, 2009


2008

de Wit C, Boettcher M, Schmidt VJ
Signaling across myoendothelial gap junctions - Fact or fiction?
Cell Commun Adhes 15: 231-45, 2008

Jelkmann W
Developments in the therapeutic use of erythropoiesis stimulating agents.
Br J Haematol 141: 287-97, 2008

 

Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ
The erythropoietin receptor in normal and cancer tissues.
Crit Rev Oncol Hematol 67: 39-61, 2008


Pries AR, Habazettl H, Ambrosio G, Hansen PR, Kaski JC, Schächinger V,
Tillmanns H, Vassalli G, Tritto I, Weis M, de Wit C, Bugiardini R
A review of methods for assessment of coronary microvascular disease in
both clinical and experimental settings

Cardiovasc Res 80: 165-74, 2008

Schmidt VJ, Wölfle SE, Boettcher M, de Wit C
Gap junctions synchronize vascular tone within the microcirculation
Pharmacol Rep 60: 68-74, 2008


Schön MR, Hogrebe E, Hengstler JG, Donaubauer B, Faber SC, Bauer A, Pietsch UC, Jelkmann W, Thiery J, Hauss JP, Tannapfel A
Erythropoietin stimulates hepatocyte regeneration after liver resection.
Excli J 7: 79-92, 2008


2007

Brügge K, Jelkmann W, Metzen E

Hydroxylation of Hypoxia-Inducible Transcription Factors and Chemical Compounds Targeting the HIF-alpha Hydroxylases.

Curr Medicinal Chem 14: 1853-1862, 2007

 

de Wit C
Closing the gap at hot spots (invited editorial)
Circ Res 100: 931-933, 2007


de Wit C, Wölfle SE
EDHF and gap junctions: Important regulators of vascular tone within the microcirculation.
Curr Pharm Biotechnol 8: 11-25, 2007

 

Dunst J, Metzen E, Rades D
Erythropoietin in der Strahlentherapie.
Onkologe J 13:143-149, 2007


Jelkmann W
Control of erythropoietin gene expression and its use in medicine.
Methods Enzymol 435: 179-97, 2007

 

Jelkmann W
Erythropoietin after a century of research: younger than ever.
Eur J Haematol 78: 183-205, 2007


Jelkmann W
Novel erythropoietic agents: A threat to sportsmanship.
Medicina Sportiva 11: 32-42, 2007


Jelkmann W, Laugsch M
 Problems in identifying functional erythropoietin receptors in cancer tissue (Letter).
J Clin Oncol 25: 1627-1628, 2007

Jelkmann W
Recombinant EPO production-points the nephrologist should know.
Nephrol Dial Transplant 22: 2749-53, 2007


2006

de Wit C, Hoepfl B, Wölfle SE 
Endothelial mediators and communication through vascular gap junctions.
Biol Chem 387: 3-9, 2006


de Wit C, Wölfle SE, Hoepfl B
Connexin-dependent communication within the vascular wall: Contribution to the control of arteriolar diameter.
Adv Cardiol 42: 268-283, 2006


2005

Jelkmann W
Effects of erythropoietin on brain function.
Curr Pharm Biotechnol 6: 65-79, 2005

 

Jelkmann W, Wagner KF

Erythropoietic and non-erythropoietic actions of erythropoietin.

Recent Res Devel Haematol 2: 33-59, 2005

 

Rossert J; Pure Red Cell Aplasia Global Scientific Advisory Board (GSAB)
Erythropoietin-induced, antibody-mediated pure red cell aplasia.
Eur J Clin Invest 35: 95-9, 2005

 

 



2004

 

de Wit C

Connexins pave the way for vascular communication.

News Physiol Sci 19: 148-53 , 2004

 

Metzen E, Ratcliffe PJ

HIF hydroxylation and cellular oxygen sensing.

Biol Chem. 385: 223-30, 2004

 

Jelkmann W , Wagner K

Beneficial and ominous aspects of the pleiotropic action of erythropoietin.

Ann Hematol 83: 673-86, 2004

 

Jelkmann W

Molecular biology of erythropoietin.

Intern Med 43: 649-59, 2004

 

Pagel H, Hoffmann G, Fuchs D, Schobersberger W

On the Mechanisms of the Neopterin-induced Suppression of Renal Erythropoietin Production.

Pteridines 15: 28-32, 2004

 


2003

Jelkmann W

Erythropoietin.

J Endocrinol Invest 26: 832-837, 2003

 

Jelkmann W

The metabolic fate of circulating erythropoietin: Insights from the pharmacokinetics of recombinant human erythropoietin and novel erythropoiesis-stimulating protein.

Clin Impl Anemia Oncol 1: 7-9, 2003

 



2002

 

Jelkmann W 

The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP.

Eur J Haematol 69: 265-74, 2002

 

Klinger MH, Jelkmann W

Review: role of blood platelets in infection and inflammation.

J Interfer Cytokine Res 22: 913-22, 2002


Wolber EM, Jelkmann W

Thrombopoietin: the novel hepatic hormone.

News Physiol Sci 17: 6-10, 2002